RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate

The United States Patent and Trademark Office (USPTO) granted a further method of use patent for RedHill Biopharma Ltd's RDHL COVID-19 treatment, opaganib.
The move grants a new method of use patent to inhibit COVID-19 in patients with pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.
The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.
Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.
In the analysis of 251 participants requiring a FiO2 up to and including 60% at baseline (54% of study participants), oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation.
Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.
Price Action: RDHL shares are up 50.90% at $0.70 on the last check Wednesday.